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Infections
To the Editor—We read with great in-
terest the report by Hsieh et al [1] in the
1 October 2009 issue of the journal on
gram-negative prosthetic joint infections
(GN PJIs). We congratulate the authors
for their substantial contribution.
The authors revealed that treating GN
PJI with debridement was associated with
a lower 2-year cumulative probability of
success than treating gram-positive (GP)
PJI with debridement (27% vs 47% of ep-
isodes were successfully treated) [1]. This
difference vanishes when 2-stage exchange
is performed and stands in contrast to
higher success rates of 40% [2] or 80%
[2–4], even if the literature usually mixes
up GP and GN organisms or concentrates
only on GP organisms [4]. Hsieh et al [1]
could not identify a statistically significant
risk factor, probably because their study
was underpowered. We think that the at-
tribution of the 6 GN PJI cases with sinus
tracts to the debridement-and-retention
arm may have decreased the success rate.
As shown in the authors’ Table 5, no ep-
isode with a sinus tract has been cured
with retention alone. This strong risk for
treatment failure is congruent with expert
opinion [5, 6].
Second, we were surprised to find that
a sinus tract was already present in 6
(22%) of 27 episodes of PJI occurring
among patients who underwent debride-
ment and retention of the prosthesis, de-
spite a maximal duration of clinical symp-
toms of 19 days. It is not clear how many
episodes of GN PJI were hematogenous,
but the median C-reactive protein level of
39 mg/L suggests that there was not a very
impressive evolution of the disease in the
majority of cases. Personally, we have had
a different clinical experience with cases
of GN PJI in Geneva. We performed a
prospective observational study during the
period from 1996 through 2007. Of 144
episodes of PJI identified, 29 (20%) were
episodes of GN PJI, of which 26 were
nonpseudomonal infections and 3 were
infections due to Pseudomonas aeruginosa.
In the study by Hsieh et al [1], there were
21 (40%) of 53 episodes of GN PJI due
to P. aeruginosa; in our study, there were
3 (10%) of 29 episodes of GN PJI due to
P. aeruginosa. Also, in our study, a sinus
tract was present in 10 (34%) of 29 epi-
sodes, but in these episodes, the sinus tract
occurred after a much longer duration of
symptoms (median duration, 33 days),
compared with the duration of symptoms
(range, 2–19 days) for all episodes of GN
PJI in the study by Hsieh et al [1]. In our
study, patients with GN PJI had the same
age as those with GP PJI (median age, 77
years) and a similar overall cure rate: 23
(79%) of 29 patients with GN PJI were
cured, and 89 (77%) of 115 patients with
GP PJI were cured ( , determinedPp .82
by use of the x2 test).
Third, in general, the GN PJI group is
too heterogeneous to be mixed up, and
should be separated between P. aeruginosa
and other GN organisms stratified in fur-
ther trials. Likewise, anaerobes should be
kept apart from the GN PJI group (which
had not been done in the study by Hsieh
et al [1]). In larger trials, P. aeruginosa
might yield a higher recurrence rate, as
clinical experience often suggests. How-
ever, in our underpowered analysis, the
overall cure rate for patients with P. aeru-
ginosa infection was unchanged, com-
pared with the overall cure rate for pa-
tients infected with other GN organisms:
2 (67%) of 3 patients with P. aeruginosa
infection were cured, and 21 (81%) of 26
patients infected with other GN organisms
were cured ( , determined by usePp .52
of the Fisher exact test). For the subgroup
of patients treated with implant retention
alone, the findings were similar: 2 (100%)
of 2 patients with P. aeruginosa infection
were cured, and 10 (71%) of 14 patients
infected with other GN organisms were
cured ( , determined by the FisherP 1 .99
exact test).
Acknowledgments
Potential conflicts of interest. Both authors:
no conflicts.
Ilker Uc¸kay1,2 and Louis Bernard1,3
1Orthopaedic Surgery Service and 2Service
of Infectious Diseases, Geneva University Hospitals,
Geneva, Switzerland; and 3Division of Infectious
Diseases, Bretonneau Hospital, Tours, France
References
1. Hsieh PH, Lee MS, Hsu KY, Chang YH, Shih
HN, Ueng SW. Gram-negative prosthetic joint
infections: risk factors and outcome of treat-
ment. Clin Infect Dis 2009; 49:1036–1043.
2. Marculescu CE, Berbari EF, Hanssen AD, et al.
Outcome of prosthetic joint infections treated
with debridement and retention of compo-
nents. Clin Infect Dis 2006; 42:471–478.
3. Byren I, Bejon P, Atkins BL, et al. One hundred
and twelve infected arthroplasties treated with
‘DAIR’ (debridement, antibiotics and implant
retention): antibiotic duration and outcome. J
Antimicrob Chemother 2009; 63:1264–1271.
4. Meehan AM, Osmon DR, Duffy MC, Hanssen
AD, Keating MR. Outcome of penicillin-sus-
ceptible streptococcal prosthetic joint infection
treated with debridement and retention of the
prosthesis. Clin Infect Dis 2003; 36:845–849.
5. Zimmerli W, Trampuz A, Ochsner PE. Pros-
thetic joint infections. N Engl J Med 2004; 351:
1645–1654.
6. Bernard L, Hoffmeyer P, Assal M, et al. Trends
in the treatment of orthopaedic prosthetic in-
fections. J Antimicrob Chemother 2004; 53:
127–129.
Reprints or correspondence: Dr Ilker Uc¸kay, Orthopaedic Sur-
gery Service and Service of Infectious Diseases, Geneva Uni-
versity Hospitals, Rue Gabrielle Perret-Gentil 4, 1211 Geneva
14, Switzerland (ilker.uckay@hcuge.ch).
Clinical Infectious Diseases 2010; 50:795
 2010 by the Infectious Diseases Society of America. All
rights reserved. 1058-4838/2010/5005-0025$15.00
DOI: 10.1086/650540
